Boehringer Ingelheim (Canada) Ltd et al. v Jamp Pharma Corportation
2022
T-2318-22
Pending
New PM(NOC) Regulations
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).
Counsel to:
JAMP Pharma Corporation
The decision is reported
here.
Meet the team
![Warren Sprigings](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0b602718f3580ecb0cc1e_warren-bw-min.jpg)
Warren Sprigings
Partner
![Mingquan Zhang, Ph.D.](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0bad553dd20fa3025675b_ming-bw-min.jpeg)
Mingquan Zhang, Ph.D.
Associate
![Meghan A. Dureen, Ph.D.](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0bae05e71cd3af89ae952_meghan-bw-min.jpeg)
Meghan A. Dureen, Ph.D.
Counsel
![Nathaniel Dillonsmith](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5da0bab4006d422e2353fe2b_nathaniel-bw-min.jpeg)
Nathaniel Dillonsmith
Associate
![Alexandre Lavoie](https://cdn.prod.website-files.com/5d9fc778718dbe2981337802/5f3588452d3c6c32143ccddb_alavoie.jpg)
Alexandre Lavoie
Associate